期刊文献+

ⅢC期卵巢癌患者腹腔与静脉联合化疗的临床疗效观察 被引量:1

原文传递
导出
摘要 目的探讨采取PCA方案(顺铂+环磷酰胺+多柔比星)腹腔与静脉联合化疗治疗ⅢC期卵巢癌患者的临床疗效。方法56例ⅢC期卵巢癌患者按治疗方法不同分为腹腔与静脉联合化疗组(联合组,30例)和单纯静脉化疗组(对照组,26例)。分别观察比较两组的临床有效率和1、3年生存率。结果联合组术后6个月有效率及1、3年生存率[分别为96.7%(29/30)、86.7%(26/30)和56.7%(17/30)]明显高于对照组[分别为76.9%(20/26)、61.5%(16/26)和30.8%(8/26)](P〈0.05)。结论ⅢC期卵巢癌患者腹腔与静脉联合化疗的疗效优于单纯静脉化疗。
出处 《中国医师进修杂志》 2011年第33期43-44,共2页 Chinese Journal of Postgraduates of Medicine
  • 相关文献

参考文献8

二级参考文献17

  • 1刘继红,李孟达.卡铂腹腔化疗腹膜后淋巴结内的药物浓度[J].中华妇产科杂志,1995,30(5):273-275. 被引量:24
  • 2高金玲,陈加廷.卵巢癌术后腹腔化疗35例分析[J].哈尔滨医药,2005,25(5):23-24. 被引量:4
  • 3郭萍.腹腔化疗治疗晚期卵巢癌的临床评价[J].卫生职业教育,2005,23(23):98-99. 被引量:3
  • 4Markman M,Reichaman B,Hakes T,et al.Intraperitoneal chemotherapy in the management of ovarian cancer [J].Cancer,1993,71 (4 Suppl):1565.-1570.
  • 5Shapiro F,Schneider J,Markman M,et al.High-intensity intravenous cyclophosphamide and cisplatinan,interim surgical debulking,and intraperitoneal cisplatin in advanced ovarian cancinoma:a pilot trial with ten-year follow-up [J].Gynecol Oncol,1997,67(1)39-45.
  • 6Morgan RJ Jr,Doroshow JH,Synold T,et al.Phase Ⅰ trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity:dose-limiting toxicity and pharmacokinetics [J].Clin Cancer Res,2003,9 (16 Pt1) :5896-5901.
  • 7曹泽毅.中华妇产科学[M].北京:人民卫生出版社,2004.2170-2172.
  • 8David S,Alberts,MD,Liu PY,et al.Intraperitonal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage Ⅲ ovarian cancer [J].N Eng J Med,1996,26 (12):1950-1955.
  • 9Fujiwara K,Sakuragi N,Suzuki S,et al.First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma:results of long-term follow-up [J].Gynecol Oncol,2003,90(3) :637-643.
  • 10Fujiwara K,Markman M,Morgan M,et al.Intraperitoneal carbo-platin-based chemotherapy for epithelial ovarian cancer[J].Gynecol Oncol,2005,97(1) :10-15.

共引文献5

同被引文献5

  • 1Liao J,Qian F,Tchabo N,et al.Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation,Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism[J].PLoS One,2014,9(1):e84941.
  • 2Andriole GL,Crawford ED,Grubb RL 3rd,et al.Prostate cancer screening in the randomized Prostate,Lung,Colorectal,and Ovarian Cancer Screening Trial:mortality results after 13 years of follow-up[J].J Natl Cancer Inst,2012,104(2):125-132.
  • 3Marcus CS,Maxwell GL,Darcy KM,et al.Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer[J].J Cancer,2014,5 (1):25-30.
  • 4Stark D,Nankivell M,Pujade-Lauraine E,et al.Standard chemotherapy with or without bevacizumab in advanced ovarian cancer:quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial[J].Lancet 0ncol,2013,14 (3):236-243.
  • 5崔开颖,朱根海,杨舒盈.紫杉醇联合顺铂静脉腹腔化疗治疗晚期卵巢癌的疗效分析[J].中国肿瘤临床与康复,2013,20(5):498-501. 被引量:35

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部